Vitiligo

AMERICAN SKIN ASSOCIATION ANNOUNCES 2023 RESEARCH GRANTS FOR SKIN CANCER AND DISEASES

Retrieved on: 
Monday, July 3, 2023
ASA, Skin, University of Massachusetts, Icahn School of Medicine at Mount Sinai, Eastern Virginia Medical School, Skin cancer, Atopic dermatitis, Prognosis, Research, Mount Sinai, Doctor of Philosophy, Melanoma, Depigmentation, Name, Dermatology, MAC, Physician, HMF, Diagnosis, Patient, Johns Hopkins School of Medicine, Melanoma Research, Pharmaceutical industry, Psoriasis, MD, Vitiligo, Medicine

NEW YORK, July 3, 2023 /PRNewswire/ -- American Skin Association has announced the names of the four Research Scholar Awards.

Key Points: 
  • NEW YORK, July 3, 2023 /PRNewswire/ -- American Skin Association has announced the names of the four Research Scholar Awards.
  • In addition, one research grant and nine medical student grants — made possible through the generosity of individuals, foundations, and corporations — were also announced.
  • "These grants support cutting-edge dermatological research that is crucial in advancing ASA's goal of defeating skin cancers like melanoma.
  • ASA provides significant research awards to established investigators and medical students studying melanoma, non-melanoma skin cancer, and other skin diseases.

Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-Inflammatory Peptide Therapeutic for Atopic Dermatitis

Retrieved on: 
Wednesday, June 28, 2023
Learning, Xeroderma, Dermatitis, Personalized medicine, Clinical trial, CF3, Quality of life, Hope, Atopic dermatitis, Research, Inflammation, Lupus, Psoriasis, Placebo, Patient, Knowledge, Vitiligo, Therapy, Gene, Red, Safety, Pharmaceutical industry, Vaccine

Atopic dermatitis, also known as eczema, affects millions of adults worldwide, causing intense itching, redness, and dry skin (1).

Key Points: 
  • Atopic dermatitis, also known as eczema, affects millions of adults worldwide, causing intense itching, redness, and dry skin (1).
  • With this topical formulation of AMTX-100 CF3, Amytrx Therapeutics aims to revolutionize the treatment landscape and offer hope to those living with atopic dermatitis.
  • "We are thrilled to initiate the open enrollment for our Phase 2b clinical trial of AMTX-100 CF3," said Dr. Matthew A. Gonda, CEO of Amytrx Therapeutics.
  • The open enrollment for the Phase 2b clinical trial of AMTX-100 CF3 is now underway.

Can I put cortisone on my face? The right advice on creams to fix irritated skin

Retrieved on: 
Tuesday, June 20, 2023
Rosacea, Human, Skin, Vein, Atrophoderma, Education, Face, Solution, Dermatitis, Connective tissue, Telangiectasia, Finger, Cortisone, Acne, Research, Psoriasis, Capillary, Perioral dermatitis, Hydrocortisone, Erythema, Patient, Risk, Steroid, Vitiligo, Sunburn, Glycosaminoglycan, Groin, Maharashtra University of Health Sciences, News, Red, Sulfur, Vaccine, Dietary supplement, Mineral oil, Cosmetics, Topical medication

Topical corticosteroids, also referred to as corticosteroids or cortisone, are the go-to treatment for many skin disorders including eczema, dermatitis and psoriasis.

Key Points: 
  • Topical corticosteroids, also referred to as corticosteroids or cortisone, are the go-to treatment for many skin disorders including eczema, dermatitis and psoriasis.
  • They can be found in various forms such as creams, ointments, and solutions.
  • Topical corticosteroids come in different strengths, from mild (such as 0.5% Hydrocortisone, available over the counter) to very potent prescription formulations.

‘Use sparingly’

    • Such warnings ignore the fact many patients are prescribed modest-strength topical steroids, which are safe and effective when used properly.
    • From the patient’s perspective, the current warnings lump all steroids together regardless of their potential for side effects.

Mixed messages

    • Or hit the problem hard with a stronger concentration for less time?
    • If cortisone is extensively used, it is advised adults and children should be examined yearly for side effects.
    • Skin atrophy (or deterioration) is the most common side effect of topical corticosteroids and manifests as tiny degenerative alterations within a few weeks.

Skin thinning

    • Repeated use in the same spot on the body results in alterations to the skin’s connective tissue and epidermal thinning.
    • That can result in lax, translucent, wrinkled skin as well as striae (stretch marks), fragility, hypo-pigmentation (fading) and the prominence of underlying veins.
    • The good news is that once topical corticosteroids are stopped, short-term atrophy from treatment can be reversed, although skin normalisation may take months.

Can you use it safely on your face?

    • Using strong cortisone creams or ointments on the face can lead to steroid dependence.
    • Topical steroids on the face can cause symptoms sometimes referred to as “red face syndrome”, dermatitis rosaceaformis steroidica or steroid addiction.
    • And stopping steroid use on the face after an extended period can have considerable rebound effects including erythema (redness), burning and scaling.

The bottom line

    • To avoid skin damage, corticosteroids should only be used on skin affected by a skin disease.
    • Finally, treatment should be customised based on the person’s symptoms, the body parts affected and how long treatment might be required.
    • This article reflects the views of the author and
      should not be construed to represent views or
      policies.

AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients

Retrieved on: 
Friday, June 16, 2023
Avita Medical, AVH, CRC, Food, ASX, Regenerative medicine, PMA, Patient, Standard of care, Vitiligo, FDA, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Skin, Safety, Pharmaceutical industry

RECELL for repigmentation of stable depigmented vitiligo lesions is the first FDA-approved therapeutic device offering a one-time treatment at the point-of-care.

Key Points: 
  • RECELL for repigmentation of stable depigmented vitiligo lesions is the first FDA-approved therapeutic device offering a one-time treatment at the point-of-care.
  • Using the device, a clinician prepares and delivers autologous skin cells from pigmented skin to stable depigmented areas, offering a safe and effective treatment for vitiligo.
  • “RECELL represents first-in-class treatment for repigmentation through the delivery of normal, healthy skin cells,” said Jim Corbett, Chief Executive Officer of AVITA Medical.
  • “This is a breakthrough approval for AVITA Medical, significantly expanding the clinical applications for RECELL, and demonstrates our continued commitment to patient care.

AMERICAN ACADEMY OF DERMATOLOGY: HOW TO CARE FOR SKIN WITH VITILIGO

Retrieved on: 
Tuesday, June 13, 2023
Learning, Dihydroxyacetone, Hair, Depression, University, Skin, Skin cancer, Clothing, Light, Nail, SPF, Doctor of Philosophy, FAAD, Dermatology, UPF, Patient, Vitiligo, AAD, University of Massachusetts Chan Medical School, Risk, Immune system, Diagnosis, Sunburn, Burns, Health, Tanning, Mental health, Injury, Disease, Cosmetics, MD

ROSEMONT, Ill., June 13, 2023 /PRNewswire/ -- Vitiligo is a disease that causes the skin to lose its natural color, resulting in light or white patches of skin. This condition, which affects people of all ages and ethnicities, not only affects patients' skin, but also can cause low self-esteem and depression, and be associated with other medical conditions.

Key Points: 
  • "However, there are some ways people can care for themselves to prevent vitiligo from spreading."
  • In recognition of Vitiligo Awareness Month in June, Dr. Mahmoud and the AAD recommend people with vitiligo follow these skin wellness tips:
    Protect your skin from the sun.
  • Use makeup, self-tanner, or skin dyes if you'd like to add color to your skin.
  • This video is part of the AAD's "Your Dermatologist Knows" series, which offers tips people can use to properly care for their skin, hair, and nails.

Codex Labs Introduces Integrative Medical Advisory Board

Retrieved on: 
Thursday, May 25, 2023
University, Pediatrics, Skin, Melasma, Alternative medicine, California State University, University of California, Davis, Ageing, Skin cancer, Quality of life, Northwestern, AP, Research, Mindfulness, Associate, Psoriasis, Inflammation, Silicon, Chicago, RNCP, MAB, Dermatoscopy, Vitiligo, Northwestern University, Jan Vansina, Pharmaceutical industry, Fine chemical, Medical device, Dermatology, MD, Ayurveda

San Jose, CA, May 25, 2023 (GLOBE NEWSWIRE) -- Codex Labs, a Silicon Valley bio-skintech company, announced an expanded medical advisory board (MAB) to support its focus on integrative skin-gut-brain solutions.

Key Points: 
  • San Jose, CA, May 25, 2023 (GLOBE NEWSWIRE) -- Codex Labs, a Silicon Valley bio-skintech company, announced an expanded medical advisory board (MAB) to support its focus on integrative skin-gut-brain solutions.
  • The Chairman of the MAB is Dr. Raja Sivamani, MD MS AP, is an integrative dermatologist, bioengineer, and Ayurvedic practitioner.
  • He is the founding director of the Chicago Integrative Eczema Center and a board member of the National Eczema Association.
  • She is also board certified in Integrative Medicine and Lifestyle Medicine, and is active on the American Board of Integrative Medicine.

AMERICAN SKIN ASSOCIATION ANNOUNCES 2023 RESEARCH ACHIEVEMENT AWARDS

Retrieved on: 
Wednesday, May 17, 2023
ASA, AWARD, Oregon Health and Science University Center for Women's Health, ISID, Skin cancer, Public policy, Atopic dermatitis, Research, Keio University, Inflammation, Doctor of Philosophy, Autoimmunity, Homeostasis, Peripheral tolerance, Psoriasis, Oregon Health & Science University, Professor, Pemphigus, International Society for Bipolar Disorders, Melanoma, Allergy, GEORGE, Ponce Health Sciences University, Vitiligo, Skin, Medical device, Dermatology, MD

NEW YORK, May 17, 2023 /PRNewswire/ -- American Skin Association (ASA) announced the recipients of the 2023 David Martin Carter Mentor Award, 2023 George W. Hambrick Award, and the 2023 Research Achievement Awards at the International Societies for Investigative Dermatology (ISID) in Tokyo, Japan.

Key Points: 
  • MASAYUKI AMAGAI, MD, PhD 2023 RECIPIENT OF GEORGE W. HAMBRICK AWARD
    NEW YORK, May 17, 2023 /PRNewswire/ -- American Skin Association (ASA) announced the recipients of the 2023 David Martin Carter Mentor Award, 2023 George W. Hambrick Award, and the 2023 Research Achievement Awards at the International Societies for Investigative Dermatology (ISID) in Tokyo, Japan.
  • "ASA is honored to recognize Dr. Hanifin and Dr. Amagai and all the 2023 Research Achievement Award recipients for their tireless efforts in the field of dermatology.
  • Dr. Amagai's clinical and research interests center on autoimmune and allergic skin diseases, skin barrier, and skin immunology.
  • ASA's Research Achievement Awards were instituted in 1989 to help identify established scientists in investigative dermatology and cutaneous biology.

NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Monday, May 15, 2023
Sclerosis, AIM, Infection, Stroke, GAAP, Multiple sclerosis, Immunotherapy, Bangladesh Technical Education Board, ASCO, National Institute of Neurological Disorders and Stroke, DSM-IV codes, Pemphigus, Transplant, NEXI, BCMA, Vitiligo, Research, Autoimmunity, Vaccine, Pharmaceutical industry

“This is an exciting time for NexImmune, as we remain focused on progressing the development of novel approaches in the field of immunotherapy,” said Kristi Jones, NexImmune’s CEO.

Key Points: 
  • “This is an exciting time for NexImmune, as we remain focused on progressing the development of novel approaches in the field of immunotherapy,” said Kristi Jones, NexImmune’s CEO.
  • “Interest in antigen specific approaches for oncology, autoimmune disorders and infectious diseases has never been higher.
  • Based upon current operating plans, NexImmune expects that its existing cash and cash equivalents will enable the Company to fund its operating and capital expenditure requirements into the fourth quarter of 2023.
  • Research and development expenses were $6.1 million in the first quarter of 2023, compared to $10.4 million for the same period in the prior year.

STRATA Skin Sciences Enters India Market with Exclusive Distribution Agreement with Spectra Medical

Retrieved on: 
Monday, May 15, 2023
Strata Skin Sciences, Partnership, Prevalence, Marketing, STRATA, Acne, Psoriasis, Light, SSKN, Dermatology, Laser, Vitiligo, Pharmaceutical industry, HORSHAM

HORSHAM, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it has entered into an exclusive, three-year agreement with Spectra Medical India Pvt Ltd., a distribution company representing medical laser and aesthetic equipment manufacturers, for the distribution of TheraClear®X, VTRAC®, and XTRAC® in India.

Key Points: 
  • India has the highest prevalence of vitiligo in the world, at about 8.8%1
    HORSHAM, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it has entered into an exclusive, three-year agreement with Spectra Medical India Pvt Ltd., a distribution company representing medical laser and aesthetic equipment manufacturers, for the distribution of TheraClear®X, VTRAC®, and XTRAC® in India.
  • “We are excited to expand into the acne, psoriasis, and vitiligo market in India with Spectra Medical,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences.
  • “Led by Ramamoorthy Sundaram, Spectra Medical has over 20 years of experience in the medical distribution industry, and is India’s leading distributor of dermatology medical devices.
  • India presents STRATA with a unique opportunity as there are no excimer laser solutions for phototherapy treatments currently available today.

AVITA Medical Reports First Quarter Financial Results and Affirms Full Year Guidance

Retrieved on: 
Thursday, May 11, 2023
Avita Medical, AVH, Anticipation, Senior, Telephone, Chief commercial officer, ASX, Regenerative medicine, EBITDA, PMA, Growth, Vitiligo, FDA, BARDA, Global Sales Law Project, Pharmaceutical industry, Management

Further, we are on track to submit our PMA supplement to the FDA for RECELL GO by the end of the second quarter.

Key Points: 
  • Further, we are on track to submit our PMA supplement to the FDA for RECELL GO by the end of the second quarter.
  • Mr. Bromley and Ms. Garner will report directly to Jim Corbett, Chief Executive Officer of AVITA Medical.
  • The gross profit margin was increased by 8% to 84% compared to 76% for the first quarter of 2022.
  • Authorized for release by the Chief Executive Officer of AVITA Medical, Inc.